Publications by authors named "A SALMEN"
Background: Different definitions of disability progression by Expanded Disability Status Scale (EDSS) may influence frequency and/or time to event.
Methods: In this multicenter cohort study, we included PPMS patients with follow-up ≥24 months and ≥3 available EDSS scores overall (≥1 per year). We applied 672 definitions of disability progression including different minimal EDSS increase, required confirmation and fixed/roving-baseline score.
Article Synopsis
- Understanding the impact of Multiple Sclerosis (MS) on health-related quality of life (HRQoL) is crucial, as it tends to decline with age and longer disease duration.
- The study analyzed data from the Swiss MS Registry to explore relationships between various MS disease characteristics, symptom burdens, and low HRQoL among 1,697 individuals, identifying specific factors that contribute to diminished quality of life.
- Results indicated that low HRQoL is linked to factors such as receiving invalidity insurance, experiencing depression, muscle weakness, memory issues, pain, and severe gait impairment, highlighting the need for targeted symptom management strategies.
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.
Ann Neurol
October 2024
Objective: To investigate the longitudinal dynamics of serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) levels in people with multiple sclerosis (pwMS) under B-cell depleting therapy (BCDT) and their capacity to prognosticate future progression independent of relapse activity (PIRA) events.
Methods: A total of 362 pwMS (1,480 samples) starting BCDT in the Swiss Multiple Sclerosis (MS) Cohort were included. sGFAP levels in 2,861 control persons (4,943 samples) provided normative data to calculate adjusted Z scores.
Article Synopsis
- Multiple sclerosis (MS) is a chronic disease marked by the loss of myelin, leading to neurological problems, and the endocannabinoid system (ECS) is being explored as a potential treatment target.
- A study involving 74 MS patients and 80 controls analyzed lipid levels in cerebrospinal fluid (CSF) and serum, revealing that most lipidomic changes in MS do not match between these two fluids.
- Findings showed that specific lipids, including endocannabinoids, varied by sex and age, emphasizing the need to study eCBs in CSF instead of blood to better understand MS-related changes.
Background: Treatment decisions for persons with relapsing-remitting multiple sclerosis (RRMS) rely on clinical and radiological disease activity, the benefit-harm profile of drug therapy, and preferences of patients and physicians. However, there is limited evidence to support evidence-based personalized decision-making on how to adapt disease-modifying therapy treatments targeting no evidence of disease activity, while achieving better patient-relevant outcomes, fewer adverse events, and improved care. Serum neurofilament light chain (sNfL) is a sensitive measure of disease activity that captures and prognosticates disease worsening in RRMS.
View Article and Find Full Text PDF